Leveraging Real-World Evidence to Extend Drug-Drug Interaction Assessment from Drug Development to Clinical Care: A Targeted Review of the Literature

Presented at the ISPOR Europe, November 2024
Nadia Quignot, Nina Shigesi, Kazue Kikuchi, Sophie Argon, and Isabelle Ragueneau-Majlessi

2024 ISPOR Europe Poster Presentation – RWD DDI Reviews

Abstract

Evaluating DDIs in a real-world setting is key to accurately assess the clinical and economic outcomes of drugs. Real-World Data (RWD) can help in identifying potential DDIs, assessing their clinical significance, guiding dose adjustments to manage potential DDIs, and supporting overall benefit-risk assessment of drugs or drug combinations. This literature review aimed to characterize current applications of RWD in evaluating and mitigating DDI risks, while identifying gaps to be addressed.